4. Diagnostisering og utredning

Ahn, S. K., Han, W., Moon, H. G., Kim, M. K., Noh, D. Y., Jung, B. W., Kim, S. W., & Ko, E. (2018). Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy. European journal of surgical oncology, 44(1), 53-58.

Anbazhagan, R., Fujii, H., & Gabrielson, E. (1999). Microsatellite instability is uncommon in breast cancer. Clinical cancer research, 5(4), 839-44.

Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., ... Group, S. S. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine, 380(20), 1929-1940.

Aziz, S., Wik, E., Knutsvik, G., Klingen, T. A., Chen, Y., Davidsen, B., Aas, H., Aas, T., & Akslen, L. A. (2017). Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE, 12(2), e0171853.

Baltzer, P., Mann, R. M., Iima, M., Sigmund, E. E., Clauser, P., Gilbert, F. J., Martincich, L., Partridge, S. C., ... Le Bihan, D. (2020). Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. European radiology, 30(3), 1436-1450.

Bardia, A., Cortés, J., Bidard, F. C., Neven, P., Garcia-Sáenz, J., Aftimos, P., O'Shaughnessy, J., Lu, J., ... Kaklamani, V. (2024). Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research, 30(19), 4299-4309.

Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 Suppl 1, 12-9.

Baselga, J., Im, S. A., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., ... Campone, M. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(7), 904-916.

Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C., Di Palma, S., Simony-Lafontaine, J., ... van de Vijver, M. J. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. Journal of clinical oncology, 19(8), 2263-2271.

Bishr, M. K., Humphreys, A., Ahmed, M., Cox, K., Hughes, A., Isherwood, J., Pinder, S. E., Remoundos, D. D., ... Whisker, L. (2025). Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery. British journal of surgery, 112(8), znaf152.

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., ... Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery, 3(2), 224-37.

Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM: classification of malignant tumours. John Wiley & Sons.

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology, 30(8), 1194-1220.

Chong, A., Weinstein, S. P., McDonald, E. S., & Conant, E. F. (2019). Digital Breast Tomosynthesis: Concepts and Clinical Practice. Radiology, 292(1), 1-14.

Cocco, E., Scaltriti, M., & Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature reviews. Clinical oncology, 15(12), 731-747.

Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M. J., ... Rolfo, C. (2022). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research, 28(7), 1302-1312.

Dickler, M. N., Saura, C., Richards, D. A., Krop, I. E., Cervantes, A., Bedard, P. L., Patel, M. R., Pusztai, L., ... Baselga, J. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical cancer research, 24(18), 4380-4387.

Elfgen, C., Leo, C., Kubik-Huch, R. A., Muenst, S., Schmidt, N., Quinn, C., McNally, S., van Diest, P. J., ... Varga, Z. (2023). Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Virchows Archiv, 483(1), 5-20.

Elfgen, C., Varga, Z., Breitling, K., Pauli, E., Schwegler-Guggemos, D., Kampmann, G., Kubik-Huch, R. A., Leo, C., ... Schrading, S. (2024). Long-Term Follow-Up of High-Risk Breast Lesions at Vacuum-Assisted Biopsy without Subsequent Surgical Resection. Breast care (Basel, Switzerland), 19(1), 62-72.

Fallenberg, E. M., Schmitzberger, F. F., Amer, H., Ingold-Heppner, B., Balleyguier, C., Diekmann, F., Engelken, F., Mann, R. M., ... Dromain, C. (2017). Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. European radiology, 27(7), 2752-2764.

Farshid, G., & Buckley, E. (2019). Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast cancer research and treatment, 174(1), 165-177.

Ferre, R., & Kuzmiak, C. M. (2022). Upgrade rate of percutaneously diagnosed pure flat epithelial atypia: systematic review and meta-analysis of 1,924 lesions. Journal of osteopathic medicine, 122(5), 253-262.

Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in oncology, 28(4), 400-418.

Forsythe, A., Zhang, W., Phillip Strauss, U., Fellous, M., Korei, M., & Keating, K. (2020). A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Therapeutic advances in medical oncology, 12, 1.758835920975613E15.

Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., ... Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. Journal of clinical oncology, 34(25), 2961-8.

Friedrich, M. (1998). MRI of the breast: state of the art. European radiology, 8(5), 707-25.

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., ... Arteaga, C. L. (2017). Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine, 9(402), eaai7993.

Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., Eriksson, S., & Arver, B. (2014). Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World journal of surgery, 38(7), 1685-93.

Groheux, D., Vaz, S. C., Poortmans, P., Mann, R. M., Ulaner, G. A., Cook, G. J. R., Hindié, E., Pilkington Woll, J. P., ... Cardoso, F. (2024). . Breast, 78, 103806.

Harvey, J. A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., Hayes, M. K., Jokich, P. M., ... Haffty, B. G. (2016). ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology : JACR, 13(11s), e31-e42.

Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016). The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clinical cancer research, 22(1), 259-67.

Hennessy, G., Boland, M. R., Bambrick, M., Crone, L., Lloyd, A., Abdelwahab, S., Downey, E., Staunton, M., ... Hill, A. D. (2022). Value of Long-term Follow-up in Surgically Excised Lesions of Uncertain Malignant Potential in the Breast - Is 5 Years Necessary?. Clinical breast cancer, 22(7), 699-704.

Houssami, N., Turner, R., & Morrow, M. (2013). Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Annals of surgery, 257(2), 249-55.

Iotti, V., Ravaioli, S., Vacondio, R., Coriani, C., Caffarri, S., Sghedoni, R., Nitrosi, A., Ragazzi, M., ... Pattacini, P. (2017). Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast cancer research, 19(1), 106.

Jochelson, M. S., & Lobbes, M. B. I. (2021). Contrast-enhanced Mammography: State of the Art. Radiology, 299(1), 36-48.

Kerlikowske, K., Molinaro, A., Cha, I., Ljung, B. M., Ernster, V. L., Stewart, K., Chew, K., Moore, D. H., & Waldman, F. (2003). Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. Journal of the National Cancer Institute, 95(22), 1692-1702.

Kim, S. B., Dent, R., Im, S. A., Espie, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., ... investigators, L. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372.

King, T. A., Pilewskie, M., Muhsen, S., Patil, S., Mautner, S. K., Park, A., Oskar, S., Guerini-Rocco, E., ... Morrow, M. (2015). Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of clinical oncology, 33(33), 3945-52.

Ko, M. J., Park, D. A., Kim, S. H., Ko, E. S., Shin, K. H., Lim, W., Kwak, B. S., & Chang, J. M. (2021). Accuracy of Digital Breast Tomosynthesis for Detecting Breast Cancer in the Diagnostic Setting: A Systematic Review and Meta-Analysis. Korean journal of radiology, 22(8), 1240-1252.

Kurata, K., Kubo, M., Kai, M., Mori, H., Kawaji, H., Kaneshiro, K., Yamada, M., Nishimura, R., ... Nakamura, M. (2020). Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 27(3), 490-498.

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., ... Diaz, L. A. ,. J. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413.

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., ... Diaz, L. A. ,. J. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 372(26), 2509-20.

Lehman, C. D., Lee, A. Y., & Lee, C. I. (2014). Imaging management of palpable breast abnormalities. AJR. American journal of roentgenology, 203(5), 1142-53.

Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., ... van der Pal, H. J. H. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, 43(41), 4229-4361.

MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., Holmes, D., Silberman, H., & Lagios, M. (2005). Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. American journal of surgery, 190(4), 521-525.

Mann, R. M., Balleyguier, C., Baltzer, P. A., Bick, U., Colin, C., Cornford, E., Evans, A., Fallenberg, E., ... Sardanelli, F. (2015). Breast MRI: EUSOBI recommendations for women's information. European radiology, 25(12), 3669-78.

Mann, R. M., Kuhl, C. K., Kinkel, K., & Boetes, C. (2008). Breast MRI: guidelines from the European Society of Breast Imaging. European radiology, 18(7), 1307-1318.

Mann, R. M., Loo, C. E., Wobbes, T., Bult, P., Barentsz, J. O., Gilhuijs, K. G., & Boetes, C. (2010). The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast cancer research and treatment, 119(2), 415-22.

Marinovich, M. L., Houssami, N., Macaskill, P., Sardanelli, F., Irwig, L., Mamounas, E. P., von Minckwitz, G., Brennan, M. E., & Ciatto, S. (2013). Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the National Cancer Institute, 105(5), 321-33.

Marinovich, M. L., Macaskill, P., Irwig, L., Sardanelli, F., von Minckwitz, G., Mamounas, E., Brennan, M., Ciatto, S., & Houssami, N. (2013). Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. British Journal of Cancer, 109(6), 1528-36.

Marinovich, M. L., Sardanelli, F., Ciatto, S., Mamounas, E., Brennan, M., Macaskill, P., Irwig, L., von Minckwitz, G., & Houssami, N. (2012). Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast, 21(5), 669-77.

Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., ... de Bono, J. S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 162-174.

Michell, M. J., & Batohi, B. (2018). Role of tomosynthesis in breast imaging going forward. Clinical radiology, 73(4), 358-371.

Mokbel, K., & Cutuli, B. (2006). Heterogeneity of ductal carcinoma in situ and its effects on management. The Lancet. Oncology, 7(9), 756-765.

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., ... Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20(5), 636-648.

Mousa-Doust, D., Dingee, C. K., Chen, L., Bazzarelli, A., Kuusk, U., Pao, J. S., Warburton, R., & McKevitt, E. C. (2022). Excision of breast fibroepithelial lesions: when is it still necessary?-A 10-year review of a regional centre. Breast cancer research and treatment, 194(2), 307-314.

Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortes, J., Blackwell, K., Soliman, H., ... Andre, F. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast cancer research, 19(1), 18.

Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S., ... Wagle, N. (2018). Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature genetics, 51(2), 207-216.

Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Christensen, I. J., & Andersen, J. A. (2000). Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast cancer research and treatment, 62(3), 197-210.

Patel, B. K., Davis, J., Ferraro, C., Kosiorek, H., Hasselbach, K., Ocal, T., & Pockaj, B. (2018). Value Added of Preoperative Contrast-Enhanced Digital Mammography in Patients With Invasive Lobular Carcinoma of the Breast. Clinical breast cancer, 18(6), e1339-e1345.

Peters, N. H., van Esser, S., van den Bosch, M. A., Storm, R. K., Plaisier, P. W., van Dalen, T., Diepstraten, S. C., Weits, T., ... Peeters, P. H. (2011). Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. European journal of cancer, 47(6), 879-86.

Petrillo, A., Fusco, R., Vallone, P., Filice, S., Granata, V., Petrosino, T., Rosaria Rubulotta, M., Setola, S. V., ... Botti, G. (2020). Digital breast tomosynthesis and contrast-enhanced dual-energy digital mammography alone and in combination compared to 2D digital synthetized mammography and MR imaging in breast cancer detection and classification. The breast journal, 26(5), 860-872.

Pinder, S. E., Shaaban, A., Deb, R., Desai, A., Gandhi, A., Lee, A. H. S., Pain, S., Wilkinson, L., & Sharma, N. (2018). NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). Clinical radiology, 73(8), 682-692.

Rakha, E. A., Pinder, S. E., Bartlett, J. M., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., ... Ellis, I. O. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. Journal of clinical pathology, 68(2), 93-9.

Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., ... Baselga, J. (2018). The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 34(3), 427-438 e6.

Rella, R., Romanucci, G., Arciuolo, D., Scaldaferri, A., Bufi, E., Croce, S., Caulo, A., & Tommasini, O. (2022). Multiple Papillomas of the Breast: A Review of Current Evidence and Challenges. Journal of imaging, 8(7)

Rigakos, G., & Razis, E. (2012). BRCAness: finding the Achilles heel in ovarian cancer. Oncologist, 17(7), 956-62.

Rubio, I. T., Wyld, L., Marotti, L., Athanasiou, A., Regitnig, P., Catanuto, G., Schoones, J. W., Zambon, M., ... Gilbert, F. (2024). European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO. European journal of surgical oncology, 50(1), 107292.

Sakakibara, M., Nagashima, T., Sangai, T., Nakamura, R., Fujimoto, H., Arai, M., Kazama, T., Hashimoto, H., ... Miyazaki, M. (2008). Breast-conserving surgery using projection and reproduction techniques of surgical-position breast MRI in patients with ductal carcinoma in situ of the breast. Journal of the American College of Surgeons, 207(1), 62-8.

Sardanelli, F., Fallenberg, E. M., Clauser, P., Trimboli, R. M., Camps-Herrero, J., Helbich, T. H., & Forrai, G. (2017). Mammography: an update of the EUSOBI recommendations on information for women. Insights Imaging, 8(1), 11-18.

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., ... Baselga, J. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute, 99(8), 628-38.

Schiaffino, S., Calabrese, M., Melani, E. F., Trimboli, R. M., Cozzi, A., Carbonaro, L. A., Di Leo, G., & Sardanelli, F. (2020). Upgrade Rate of Percutaneously Diagnosed Pure Atypical Ductal Hyperplasia: Systematic Review and Meta-Analysis of 6458 Lesions. Radiology, 294(1), 76-86.

Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., ... Turner, N. C. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of clinical oncology, 38(5), 423-433.

Schouten van der Velden, A. P., Peeters, P. H., Koot, V. C., & Hennipman, A. (2006). Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Annals of surgical oncology, 13(7), 990-998.

Schwartz, G. F., Solin, L. J., Olivotto, I. A., Ernster, V. L., & Pressman, P. I. (2000). Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer, 88(4), 946-954.

Sechopoulos, I., Suryanarayanan, S., Vedantham, S., D'Orsi, C. J., & Karellas, A. (2008). Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology, 246(2), 434-43.

Shehata, M. N., Rahbar, H., Flanagan, M. R., Kilgore, M. R., Lee, C. I., Ryser, M. D., & Lowry, K. P. (2020). Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. Journal of the American College of Radiology : JACR, 17(10), 1207-1219.

Skaane, P. (2022). Contrast-enhanced mammography for screening recalls: a problem-solving assessment tool ready for use?. European radiology, 32(11), 7386-7387.

Solorzano, S., Mesurolle, B., Omeroglu, A., El Khoury, M., Kao, E., Aldis, A., & Meterissian, S. (2011). Flat epithelial atypia of the breast: pathological-radiological correlation. AJR. American journal of roentgenology, 197(3), 740-6.

Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reutersward, C., Hakkinen, J., Degasperi, A., Amarante, T. D., ... Nik-Zainal, S. (2019). Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature medicine, 25(10), 1526-153.

Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., ... Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical cancer research, 22(15), 3764-73.

Turnbull, L., Brown, S., Harvey, I., Olivier, C., Drew, P., Napp, V., Hanby, A., & Brown, J. (2010). Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet, 375(9714), 563-71.

Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., ... Reis-Filho, J. S. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene, 29(14), 2013-23.

Turner, N., Tutt, A., & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews. Cancer, 4(10), 814-9.

Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., ... Rugo, H. S. (2023). Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine, 388(22), 2058-2070.

Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., ... Bliss, J. M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine, 24(5), 628-637.

Vasselli, F., Fabi, A., Ferranti, F. R., Barba, M., Botti, C., Vidiri, A., & Tommasin, S. (2022). How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature. Frontiers in oncology, 12, 859838.

Vaz, S. C., Woll, J. P. P., Cardoso, F., Groheux, D., Cook, G. J. R., Ulaner, G. A., Jacene, H., Rubio, I. T., ... de Geus-Oei, L. F. (2024). . European journal of nuclear medicine and molecular imaging, 51(9), 2706-2732.

Wallis, M., Tardivon, A., Helbich, T., & Schreer, I. (2007). Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. European radiology, 17(2), 581-8.

WHO Classification of Tumours Editorial Board (2019). Breast Tumours (WHO Classification of Tumours, 5th Edition, Volume 2). Lyon: IARC.

Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., ... Dowsett, M. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of clinical oncology, 36(20), 2105-2122.

Zhu, X., Huang, J. M., Zhang, K., Xia, L. J., Feng, L., Yang, P., Zhang, M. Y., Xiao, W., ... Yu, Y. H. (2018). Diagnostic Value of Contrast-Enhanced Spectral Mammography for Screening Breast Cancer: Systematic Review and Meta-analysis. Clinical breast cancer, 18(5), e985-e995.